The Immunological Impact of Neoadjuvant Chemotherapy on the Tumor Microenvironment of Esophageal Squamous Cell Carcinoma
- 6 August 2011
- journal article
- Published by Springer Science and Business Media LLC in Annals of Surgical Oncology
- Vol. 19 (5), 1713-1719
- https://doi.org/10.1245/s10434-011-1906-x
Abstract
Esophageal cancer is an aggressive cancer with poor prognosis. However, little is known about the immune response in the tumor microenvironment after neoadjuvant chemotherapy.To investigate the immunological impact of neoadjuvant chemotherapy in the tumor microenvironment of esophageal squamous cell carcinoma.Eighteen patients with esophageal squamous cell carcinoma with and without neoadjuvant chemotherapy were analyzed using immunohistochemical methods for human leukocyte antigen (HLA) class I heavy chain, CD4-, CD8-, and Foxp3-positive cell infiltration.The number of CD4 T cells in the stroma and within the cancer nest was significantly higher in the neoadjuvant chemotherapy group. The number of CD8 T cells in the stroma was significantly higher in the neoadjuvant chemotherapy group. HLA class I expression was more downregulated in the control group compared with the neoadjuvant chemotherapy group.Neoadjuvant chemotherapy utilizing 5-fluorouracil and cisplatin in esophageal squamous cell carcinoma is useful to induce CD4 and CD8 T lymphocytes in the tumor microenvironment and to maintain HLA class I expression levels in combination with its direct cytotoxic effects.Keywords
This publication has 20 references indexed in Scilit:
- Neoadjuvant treatment of esophageal cancerWorld Journal of Gastroenterology, 2010
- Cyclophosphamide Augments Antitumor Immunity: Studies in an Autochthonous Prostate Cancer ModelCancer Research, 2009
- FOCUS on FOCIS: Combined chemo-immunotherapy for the treatment of hormone-refractory metastatic prostate cancerClinical Immunology, 2009
- The relationship between tumour proliferative activity, the systemic inflammatory response and survival in patients undergoing curative resection for colorectal cancerColorectal Disease, 2008
- Combination of Docetaxel and Recombinant Vaccine Enhances T-Cell Responses and Antitumor Activity: Effects of Docetaxel on Immune EnhancementClinical Cancer Research, 2008
- Infiltrating regulatory T cell numbers is not a factor to predict patient's survival in oesophageal squamous cell carcinomaBritish Journal of Cancer, 2008
- Surgery Plus Chemotherapy Compared With Surgery Alone for Localized Squamous Cell Carcinoma of the Thoracic Esophagus: A Japan Clinical Oncology Group Study—JCOG9204Journal of Clinical Oncology, 2003
- Systemic inflammatory response predicts survival following curative resection of colorectal cancerBritish Journal of Surgery, 2003
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Preoperative Chemoradiation and Pancreaticoduodenectomy for Adenocarcinoma of the PancreasArchives of Surgery, 1992